Lupus Nephritis

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. ISN/RPS Classification
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment — Induction Therapy
  8. Treatment — Maintenance and New Agents
  9. Special Considerations
  10. Prognosis
  11. Research Papers (PubMed searches)
  12. References
  13. Featured Videos

Overview

Lupus nephritis (LN) is renal involvement in systemic lupus erythematosus (SLE), the most common and serious organ complication of the disease. Approximately 50% of SLE patients develop clinically significant LN during their lifetime, and 10–30% of those progress to end-stage renal disease (ESRD). The central mechanism involves deposition of immune complexes — driven by autoantibodies including anti-dsDNA, anti-C1q, and anti-nucleosome antibodies — within glomerular structures. These deposits activate the classical complement pathway, generating C3a and C5a, which recruit inflammatory cells and drive progressive glomerular injury. Lupus nephritis is a leading cause of morbidity and mortality in SLE, and early recognition combined with aggressive immunosuppression has dramatically improved outcomes over the past six decades.

Back to Table of Contents

Epidemiology

LN develops in approximately 50% of all SLE patients, with marked racial and ethnic disparities. Rates are highest in Black patients (60–70%) and Hispanic patients (50–60%), and lower in White patients (30–40%). Asian patients also experience higher rates and more severe renal disease compared to White patients. The female-to-male ratio in SLE is approximately 9:1, reflecting hormonal and genetic contributions. SLE incidence in the United States ranges from 5–10 per 100,000 per year, with considerably higher rates in minority women of childbearing age.

LN onset typically occurs within 3–5 years of the initial SLE diagnosis, though it can present at disease onset or emerge decades later. Black and Hispanic patients tend to develop LN earlier and with more severe histological class at presentation. Ten-year survival has improved dramatically — from below 20% in the 1950s to over 90% in contemporary cohorts in developed countries — largely due to the introduction of cyclophosphamide, mycophenolate mofetil, and biological agents. Despite this, 10–30% of LN patients still reach ESRD, with higher rates in Black patients.

Back to Table of Contents

Pathophysiology

SLE is characterized by failure of central and peripheral immune tolerance, leading to production of pathogenic autoantibodies against nuclear self-antigens. The most disease-specific are anti-dsDNA antibodies; anti-Sm, anti-C1q, and anti-nucleosome antibodies are also important. These autoantibodies bind self-antigens in circulation (forming circulating immune complexes) and within the kidney itself — nucleosomes and chromatin fragments released from apoptotic cells bind to glomerular matrix components, creating in situ immune complex formation.

Immune complex deposition occurs in distinct compartments depending on LN class: the mesangium (Class I/II), subendothelial space (Class III/IV), and subepithelial space (Class V). Subendothelial deposits are particularly inflammatory because they are accessible to circulating complement and inflammatory cells. Activation of the classical complement pathway generates C3a and C5a, which are potent chemoattractants and activators of neutrophils, monocytes, and macrophages. The resulting cytokine storm (IL-6, IL-1β, TNF-α, IFN-α) drives glomerular endothelial injury, mesangial expansion, podocyte loss, and tubulointerstitial inflammation.

B-cell survival factors BAFF (BLyS) and APRIL are elevated in SLE and perpetuate autoreactive B-cell survival and autoantibody production — the basis for belimumab therapy. The type I interferon signature (IFN-α overproduction from plasmacytoid dendritic cells stimulated by nucleic-acid-containing immune complexes via TLR7/TLR9) is a hallmark of SLE pathogenesis and correlates with disease activity, justifying anifrolumab (anti-IFN receptor) as a therapeutic target.

Back to Table of Contents

ISN/RPS Classification

Kidney biopsy remains the gold standard for LN classification. The International Society of Nephrology / Renal Pathology Society (ISN/RPS) classification, originally published in 2003 (Weening et al.) and revised in 2018 (Bajema et al.), categorizes LN by light microscopy, immunofluorescence, and electron microscopy findings:

The revised 2018 classification introduced standardized Activity Index (AI, 0–24) and Chronicity Index (CI, 0–12) scores. High AI indicates active, potentially reversible inflammation; high CI indicates fibrosis and irreversible damage. These indices inform prognosis and treatment decisions independently of histological class.

Back to Table of Contents

Clinical Presentation

Clinical features depend on histological class and disease activity. Class III/IV LN typically presents with:

Class V LN presents predominantly as nephrotic syndrome: proteinuria greater than 3.5 g/day, hypoalbuminemia, peripheral edema, and hyperlipidemia. Hematuria may be absent.

Systemic SLE features often accompany LN flares: malar rash, photosensitivity, arthritis, serositis (pleuritis, pericarditis), Raynaud phenomenon, cytopenias, and neurological involvement. The classic triad of an LN flare is rising anti-dsDNA titer + falling complement (C3, C4) + worsening urinalysis (RBC casts, increasing proteinuria).

Antiphospholipid antibodies are present in 30–40% of SLE/LN patients and confer risk of arterial and venous thrombosis, thrombocytopenia, and recurrent pregnancy loss (antiphospholipid syndrome, APS). Their presence complicates LN management and worsens renal prognosis. Distinguishing an active LN flare from a superimposed bacterial or viral infection is clinically important: both can raise creatinine; ESR rises in both; CRP rises more prominently in infection than in SLE flares.

Back to Table of Contents

Diagnosis

Kidney biopsy is required for definitive LN classification and to guide treatment intensity. It should be performed early when: (1) proteinuria exceeds 0.5 g/day combined with hematuria or RBC casts; (2) creatinine is rising unexplained by other causes; or (3) clinical suspicion is high in a known SLE patient with active urinary sediment. Biopsy can be deferred only in Class I/II suspected from mild labs or when biopsy risk is prohibitive.

Key diagnostic tests:

Back to Table of Contents

Treatment — Induction Therapy

Induction therapy targets rapid suppression of active glomerular inflammation in Class III, IV, and V (or mixed) LN. Current regimens are based on landmark randomized controlled trials and are codified in ACR 2019 and EULAR 2019 guidelines.

Glucocorticoids

High-dose glucocorticoids remain the backbone of induction. For severe or rapidly deteriorating LN (rising creatinine, crescents, nephrotic syndrome), methylprednisolone 500–1000 mg IV pulse dosing for 3 consecutive days is given first, followed by oral prednisone 0.5–1 mg/kg/day (maximum 60–80 mg/day) with gradual taper over 12–24 months. Minimize cumulative glucocorticoid exposure to reduce metabolic and infectious complications; target prednisone ≤7.5 mg/day by 6 months where possible.

Mycophenolate Mofetil (MMF)

MMF 2–3 g/day is now the preferred induction agent for most Class III/IV LN, particularly in non-Asian patients. The landmark Ginzler 2005 NEJM trial established non-inferiority of MMF to intravenous cyclophosphamide for induction, with a superior safety profile. MMF is strongly preferred over cyclophosphamide in women of reproductive age because cyclophosphamide causes premature ovarian failure in 30–60% of patients depending on cumulative dose and age at treatment.

Cyclophosphamide (CYC)

CYC remains an option for severe, crescentic, or refractory LN. The EuroLupus low-dose protocol (500 mg IV every 2 weeks for 6 doses; total 3 g) proved as effective as the original NIH high-dose protocol (0.5–1 g/m² monthly for 6 months) in European cohorts (Houssiau 2002, 10-year follow-up 2010), with substantially less gonadotoxicity. The NIH high-dose protocol is reserved for life- or organ-threatening LN, severe crescentic disease, or failure of low-dose approaches. Gonadal protection: discuss egg or sperm harvesting before therapy; GnRH agonist co-administration may help preserve ovarian reserve.

Voclosporin Triple Therapy

Voclosporin, a novel calcineurin inhibitor with a more favorable nephrotoxicity profile than tacrolimus or cyclosporine, was evaluated in the AURORA 1 trial (Rovin, Lancet 2021). Added to MMF plus low-dose steroids (triple therapy), voclosporin achieved complete renal remission in 40.8% of patients at 52 weeks versus 22.5% in the control arm. The FDA approved voclosporin for active LN (Class III, IV, V, and mixed) in January 2021. It is particularly effective for Class V (membranous) LN with heavy proteinuria and for achieving rapid proteinuria reduction.

Belimumab

Belimumab (anti-BAFF/BLyS monoclonal antibody) was evaluated in the BLISS-LN trial (Furie, NEJM 2020) as add-on therapy to standard induction (MMF + steroids or cyclophosphamide + steroids). The primary renal response was achieved in 43% of belimumab patients versus 32% of controls at 104 weeks. Belimumab became the first biologic agent FDA-approved for lupus nephritis in November 2020. It is available in both intravenous and subcutaneous formulations and is particularly beneficial for Class III/IV/V LN with persistent SLE activity or incomplete response to standard therapy alone.

Back to Table of Contents

Treatment — Maintenance and New Agents

Maintenance therapy aims to sustain remission, prevent flares, and minimize cumulative immunosuppression toxicity. It typically continues for a minimum of 3–5 years after achieving complete remission.

Mycophenolate Mofetil (Preferred Maintenance)

MMF 1–2 g/day is the preferred maintenance agent. The ALMS maintenance trial (Dooley 2011, Lancet) demonstrated MMF superiority over azathioprine for maintaining remission and preventing treatment failure (hazard ratio 0.44), establishing MMF as the first-choice maintenance agent in most patients.

Azathioprine

Azathioprine 1.5–2.5 mg/kg/day is a well-established alternative maintenance agent, preferred in patients planning pregnancy because MMF is teratogenic (Category D) and must be stopped 6 weeks before conception. AZA is considered the maintenance immunosuppressant of choice during pregnancy in LN when immunosuppression cannot be withdrawn.

Hydroxychloroquine

Hydroxychloroquine (HCQ) 5 mg/kg/day (maximum 400 mg/day) should be prescribed to all SLE patients without contraindication, and continued throughout LN treatment and maintenance. HCQ reduces the frequency of LN flares, lowers cardiovascular event rates, reduces thrombosis risk (including in APS), and independently improves long-term survival. Annual ophthalmologic screening is required due to the risk of retinal toxicity at high cumulative doses.

Belimumab (Maintenance)

Belimumab should be continued after a successful induction response and can be maintained indefinitely if tolerated. It reduces flare frequency and may allow glucocorticoid tapering.

Obinutuzumab

Obinutuzumab, a glycoengineered anti-CD20 antibody with superior B-cell depletion compared to rituximab, was evaluated in the NOBILITY trial (Furie 2022, Ann Rheum Dis). Added to MMF plus steroids, obinutuzumab achieved complete renal response in 40% of patients at 104 weeks versus 23% in the placebo arm. Regulatory review is ongoing; not yet FDA-approved for LN as of 2024.

Rituximab

Rituximab (anti-CD20) is used off-label for refractory LN. The LUNAR trial did not meet its primary endpoint, but substantial real-world evidence supports rituximab benefit in Class III/IV LN refractory to MMF and cyclophosphamide. It is widely used in clinical practice for refractory disease.

Anifrolumab

Anifrolumab (anti-IFN-α receptor type I) is approved for active non-renal SLE (TULIP trials). Its role in LN is under investigation in the IRIS trial, with promising signals in interferon-high SLE patients who have concurrent renal involvement.

SGLT2 Inhibitors

SGLT2 inhibitors (dapagliflozin, empagliflozin) are not immunosuppressants but are increasingly used as kidney-protective add-on therapy in LN-associated CKD. They reduce proteinuria, slow GFR decline, and lower cardiovascular risk. Their use in LN-CKD mirrors their established role in diabetic and non-diabetic CKD.

Back to Table of Contents

Special Considerations

Antiphospholipid Syndrome

Antiphospholipid antibodies are present in approximately 30–40% of SLE/LN patients. Those with clinical APS (thrombosis or pregnancy morbidity plus persistent antiphospholipid antibodies) require anticoagulation: warfarin targeting INR 2–3 for arterial thrombosis; INR 2–3 for venous thrombosis (some guidelines suggest 3–4 for recurrent arterial events). Hydroxychloroquine provides additional antithrombotic protection and should always be included. APS independently worsens LN prognosis and is associated with a distinct vascular renal lesion (thrombotic microangiopathy superimposed on LN).

Pregnancy and LN

Pregnancy in LN is high-risk and requires multidisciplinary management (rheumatology, maternal-fetal medicine, nephrology). Pre-pregnancy counseling: ideally achieve complete renal remission for at least 6 months before conception. Drugs to stop before conception: MMF (teratogenic; stop 6 weeks before conception) and cyclophosphamide. Hydroxychloroquine is safe throughout pregnancy and should be continued. Low-dose aspirin is recommended from the first trimester for preeclampsia risk reduction. Azathioprine plus low-dose prednisone can manage LN flares during pregnancy. Risks include preeclampsia, fetal loss, preterm delivery, intrauterine growth restriction, and neonatal lupus.

Hypertension Control

ACE inhibitors or angiotensin receptor blockers (ARBs) are the antihypertensive agents of choice in LN: they reduce proteinuria by lowering intraglomerular pressure independently of blood pressure effects. Target BP is <130/80 mmHg. ACE inhibitors and ARBs must be stopped during pregnancy. SGLT2 inhibitors add complementary renoprotection.

LN Recurrence after Renal Transplantation

LN recurs in approximately 10% of renal transplants, substantially less commonly than recurrence of IgA nephropathy or FSGS. Pre-transplant SLE activity should be controlled; HCQ continued post-transplant reduces flare risk. Standard transplant immunosuppression (tacrolimus + MMF + prednisone) also treats recurrent LN.

Infection Prophylaxis

All patients receiving cyclophosphamide or high-dose MMF with steroids require Pneumocystis jirovecii pneumonia (PCP) prophylaxis: trimethoprim-sulfamethoxazole 1 single-strength tablet 3 times per week is standard. Influenza and pneumococcal vaccination before immunosuppression initiation. Live vaccines (live-attenuated influenza, MMR, varicella) are contraindicated during active immunosuppression. Immunosuppression should be held or reduced in the setting of serious bacterial or opportunistic infections, with close monitoring for LN flare on de-escalation.

Back to Table of Contents

Prognosis

Overall 10-year survival in LN exceeds 90% in developed countries, a transformation from the less than 20% seen in the 1950s before modern immunosuppression. However, ESRD occurs in 10–30% at 10 years, with substantially higher rates in Black and Hispanic patients, reflecting both biological (higher rates of severe Class IV, higher antiphospholipid antibody burden) and socioeconomic (delayed diagnosis, access to specialty care) disparities.

Predictors of ESRD include:

The leading causes of death in LN are cardiovascular disease (accelerated atherosclerosis from chronic inflammation, glucocorticoid-induced dyslipidemia and diabetes, and renal-driven hypertension) and infections (from chronic immunosuppression). Newer agents — belimumab and voclosporin — have improved rates of complete renal remission in clinical trials; their long-term impact on ESRD prevention is under active study. Complete remission at 12 months remains the strongest modifiable predictor of long-term renal survival.

Back to Table of Contents

Research Papers (PubMed searches)

Back to Table of Contents

References

  1. Furie R, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis (BLISS-LN). N Engl J Med. 2020;383(12):1117–1128. PMID: 32937045. https://doi.org/10.1056/NEJMoa2029595
  2. Rovin BH, et al. Efficacy and Safety of Voclosporin versus Placebo for Lupus Nephritis (AURORA 1). Lancet. 2021;397(10289):2070–2080. PMID: 34015342. https://doi.org/10.1016/S0140-6736(21)00578-X
  3. Ginzler EM, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–2228. PMID: 16306519. https://doi.org/10.1056/NEJMoa043731
  4. Houssiau FA, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2002;46(8):2121–2131. PMID: 12209517. https://doi.org/10.1002/art.10461
  5. Dooley MA, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis (ALMS). N Engl J Med. 2011;365(20):1886–1895. PMID: 22087680. https://doi.org/10.1056/NEJMoa1014460
  6. Furie RA, et al. Obinutuzumab for Proliferative Lupus Nephritis (NOBILITY). Ann Rheum Dis. 2022;81(1):100–107. PMID: 34535479. https://doi.org/10.1136/annrheumdis-2021-220457
  7. Bajema IM, et al. Revision of the ISN/RPS classification for lupus nephritis: clarification of definitions, and modified NIH activity and chronicity indices. Kidney Int. 2018;93(4):789–796. PMID: 29203177. https://doi.org/10.1016/j.kint.2017.11.023
  8. Weening JJ, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–250. PMID: 14747370. https://doi.org/10.1097/01.asn.0000108969.21691.5d
  9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. PMID: 9324032. https://doi.org/10.1002/art.1780400928
  10. Bertsias GK, et al. EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. PMID: 30926590. https://doi.org/10.1136/annrheumdis-2019-215089
  11. Petri M, et al. Voclosporin as add-on therapy in lupus nephritis: long-term analysis of the AURORA Phase 3 trial. Arthritis Rheumatol. 2022;74(3):516–524. PMID: 34617413. https://doi.org/10.1002/art.41956
  12. Anders HJ, et al. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. PMID: 31974366. https://doi.org/10.1038/s41572-019-0141-9

Back to Table of Contents

Connections

Back to Table of Contents